Opportunities to Statistically Mine PAT Data for Release Testing Explored
This article was originally published in The Gold Sheet
You may also be interested in...
The pharmaceutical industry is incorporating the lifecycle approach to process validation – and seeing some of its benefits after initial misgivings – while an FDA official discussed the elements of a robust process validation program and consequences when these are not in place. Industry is developing separate guidance on designing process validation studies for biotechnological drugs.